(2017) Brunet LR, et al. SITC 2017 Annual Meeting; November 8-12, 2017; National Harbor, MD, USA. Poster 81.
Standardized whole blood stimulation system proves superior reproducibility over PBMCs
A new paper on improved methods for monitoring differential immune response activation was published in Volume 183 of the journal Clinical Immunology. Researchers report on a multi-center study in seven FOCIS Centers of Excellence to directly compare whole blood syringe-based system, TruCulture, to the current method of isolation of PBMCs for immunomonitoring.
To compare intra and inter-center variability between PBMC and TruCulture stimulation, the blood of 152 healthy donors was both stimulated in whole blood assay and after isolation of PBMC, across multiple centers. Following exposure to LPS, anti-CD3/anti-CD28, or media alone, samples were analyzed using multi-analyte profiling (MAP) for 55 proteins at Myriad RBM’s CLIA-certified laboratory. Focusing on analytes that were induced in both TruCulture and PMBC stimulation, further analysis was based on the 35 commonly induced proteins.
Biomarkers for pain assessment are needed for more accurate pain therapy treatment in patients unable to reliably self-report their circumstances such as patients with dementia, intubated patients, and infants. The authors of a study recently published in Biomarkers in Medicine, Soluble intercellular adhesion molecule-1: a potential biomarker for pain intensity in chronic pain patients, hypothesized that pain intensity might be assessable using inflammatory molecules measurable in serum.
3D Growth of Endothelial Cells During ISS Space Mission – The SPHEROIDS Project
The April 2017 issue of Biomaterials reports on an automated cell culture unit that was developed for the SpaceX CRS-ISS space mission that resulted in three dimensional growth of human endothelial cells in microgravity.
A spaceflight to the International Space Station, carried out in April – May 2016, included a study to examine endothelial cell (EC) behavior in respect to cellular proliferation and apoptosis under spaceflight conditions to examine the gravity dependency of EC tube formation.
Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human study of FR1041. OSE and collaborators at the University of Nantes and Janssen conducted a detailed phase I evaluation of safety, pharmacokinetics, pharmacodynamics and potency of FR104 in healthy volunteers.
More commonly known as an inhibitory cytokine, high doses of IL-10 have been shown to lead to the activation and survival of antigen stimulated CD8 T cells. According to a study published in the Journal of Clinical Oncology, the investigators in this first-in-human, phase 1 clinical trial of IL-10 (AM0010), demonstrate antitumor activity and therapy tolerability in a pretreated population. The primary endpoint of the study was to establish safety, tolerability and the maximum tolerated dose. This goal appears to have been met, with a low incidence of adverse events, most of which were temporary or reversible. The dose-escalation study was followed by a renal cell cancer dose-expansion cohort.